CN112204050B - 抗ms4a6a抗体及其使用方法 - Google Patents

抗ms4a6a抗体及其使用方法 Download PDF

Info

Publication number
CN112204050B
CN112204050B CN201980018630.2A CN201980018630A CN112204050B CN 112204050 B CN112204050 B CN 112204050B CN 201980018630 A CN201980018630 A CN 201980018630A CN 112204050 B CN112204050 B CN 112204050B
Authority
CN
China
Prior art keywords
antibody
amino acid
ms4a6a
antibodies
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201980018630.2A
Other languages
English (en)
Chinese (zh)
Other versions
CN112204050A (zh
Inventor
P·空
H·莱茵
T·施瓦伯
A·易
A·罗森斯奥
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alexite Co ltd
Original Assignee
Alexite Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alexite Co ltd filed Critical Alexite Co ltd
Publication of CN112204050A publication Critical patent/CN112204050A/zh
Application granted granted Critical
Publication of CN112204050B publication Critical patent/CN112204050B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CN201980018630.2A 2018-01-31 2019-01-31 抗ms4a6a抗体及其使用方法 Active CN112204050B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862624578P 2018-01-31 2018-01-31
US62/624,578 2018-01-31
US201862646846P 2018-03-22 2018-03-22
US62/646,846 2018-03-22
PCT/US2019/016141 WO2019152706A1 (en) 2018-01-31 2019-01-31 Anti-ms4a6a antibodies and methods of use thereof

Publications (2)

Publication Number Publication Date
CN112204050A CN112204050A (zh) 2021-01-08
CN112204050B true CN112204050B (zh) 2025-03-14

Family

ID=67479397

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980018630.2A Active CN112204050B (zh) 2018-01-31 2019-01-31 抗ms4a6a抗体及其使用方法

Country Status (5)

Country Link
US (2) US20210122817A1 (https=)
EP (1) EP3746484A4 (https=)
JP (2) JP2021513328A (https=)
CN (1) CN112204050B (https=)
WO (1) WO2019152706A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112204050B (zh) 2018-01-31 2025-03-14 艾莱克特有限责任公司 抗ms4a6a抗体及其使用方法
CN111971301B (zh) 2018-01-31 2025-01-07 艾莱克特有限责任公司 抗ms4a4a抗体及其使用方法
MX2022001260A (es) 2019-07-31 2022-04-18 Alector Llc Anticuerpos anti-ms4a4a y metodos de uso de los mismos.
CN115029383B (zh) * 2022-04-21 2024-02-20 苏天生命科技(苏州)有限公司 Ms4a3蛋白在调控红细胞成熟中的应用
CN116219009B (zh) * 2022-10-19 2024-10-01 杭州师范大学 小胶质细胞特异性表达的ms4a6a在胶质母细胞瘤治疗或预后评估试剂盒上的应用
US20250134920A1 (en) 2023-10-30 2025-05-01 Regeneron Pharmaceuticals, Inc. Treatment Of Myeloid Cell Dysfunction With Membrane Spanning 4-Domains A6A (MS4A6A) Inhibitors

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017143036A1 (en) * 2016-02-16 2017-08-24 President And Fellows Of Harvard College Modulators of ms4a activity

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002251692A1 (en) 2000-12-08 2002-08-19 Duke University Identification of novel ms4a gene family members expressed by hematopoietic cells
GB0125338D0 (en) 2001-10-22 2001-12-12 Isis Innovation Process for reducing immunogenic reactions using selective TH1 cell binding antibodies
GB0324888D0 (en) 2003-10-24 2003-11-26 Novartis Ag Organic compounds
CN101001879A (zh) 2004-06-14 2007-07-18 伊利诺伊大学董事会 与胎儿而非成体cd34+/cd36+细胞结合的抗体
JP2008506637A (ja) * 2004-06-14 2008-03-06 ザ・ボード・オブ・トラスティーズ・オブ・ザ・ユニバーシティ・オブ・イリノイ 胎児起源の細胞に対する抗体
GB0624500D0 (en) 2006-12-07 2007-01-17 Istituto Superiore Di Sanito A novel passive vaccine for candida infections
EP2108701A1 (en) 2008-04-10 2009-10-14 Ganymed Pharmaceuticals AG Methods involving MS4A12 and agents targeting MS4A12 for therapy, diagnosis and testing
EP2390349A1 (en) * 2010-05-25 2011-11-30 Sanofi Methods and uses relating to the identification of compound involved in pain as well as methods of diagnosing algesia
CN104774264B (zh) * 2014-01-15 2018-09-14 上海易乐生物技术有限公司 抗人proBDNF单克隆抗体及其在疼痛中的作用
CA2874083C (en) 2014-12-05 2024-01-02 Universite Laval Tdp-43-binding polypeptides useful for the treatment of neurodegenerative diseases
CN105759057A (zh) * 2016-04-12 2016-07-13 上海凯璟生物科技有限公司 一种检测阿尔兹海默综合症ms4a6a的干式免疫荧光试剂盒和制备方法
CN105969901B (zh) * 2016-07-27 2019-10-11 北京泱深生物信息技术有限公司 Ms4a6a作为多发性骨髓瘤诊治标志物的用途
CN112204050B (zh) 2018-01-31 2025-03-14 艾莱克特有限责任公司 抗ms4a6a抗体及其使用方法
CN111971301B (zh) 2018-01-31 2025-01-07 艾莱克特有限责任公司 抗ms4a4a抗体及其使用方法
MA54880A (fr) 2019-02-01 2021-12-08 Avrobio Inc Compositions et procédés de traitement de troubles neurocognitifs
MX2022001260A (es) 2019-07-31 2022-04-18 Alector Llc Anticuerpos anti-ms4a4a y metodos de uso de los mismos.
MX2022004678A (es) 2019-10-22 2022-08-15 Biogen Ma Inc Anticuerpo anti-beta amiloide para el tratamiento de la enfermedad de alzheimer.
WO2024086796A1 (en) 2022-10-20 2024-04-25 Alector Llc Anti-ms4a4a antibodies with amyloid-beta therapies

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017143036A1 (en) * 2016-02-16 2017-08-24 President And Fellows Of Harvard College Modulators of ms4a activity

Also Published As

Publication number Publication date
WO2019152706A1 (en) 2019-08-08
US20210122817A1 (en) 2021-04-29
JP2021513328A (ja) 2021-05-27
EP3746484A4 (en) 2021-11-17
US12215149B2 (en) 2025-02-04
US20220380455A1 (en) 2022-12-01
CN112204050A (zh) 2021-01-08
JP2023113896A (ja) 2023-08-16
EP3746484A1 (en) 2020-12-09

Similar Documents

Publication Publication Date Title
CN111971301B (zh) 抗ms4a4a抗体及其使用方法
CN112204050B (zh) 抗ms4a6a抗体及其使用方法
CN114341181B (zh) 抗ms4a4a抗体及其使用方法
CN111886246B (zh) 抗tmem106b抗体及其使用方法
US20240294650A1 (en) Anti-mertk antibodies and methods of use thereof
WO2023010076A1 (en) Anti-sirp-alpha antibodies and methods of use thereof
CN116981696A (zh) 抗tmem106b抗体及其使用方法
HK40036037A (en) Anti-ms4a6a antibodies and methods of use thereof
HK40034438A (zh) 抗ms4a4a抗体及其使用方法
HK40063237A (en) Anti-ms4a4a antibodies and methods of use thereof
HK40036920A (en) Anti-tmem106b antibodies and methods of use thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40036037

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant